BIKTARVY®

bictegravir, emtricitabine and tenofovir alafenamide

Consumer Medicine Information

This leaflet provides important information about using BIKTARVY. You should also speak to your doctor or pharmacist if you would like further information or if you have any concerns or questions about using BIKTARVY.

Where to find information in this leaflet:

1. Why am I using BIKTARVY?

- 2. What should I know before I use BIKTARVY?
- 3. What if I am taking other medicines?
- 4. How do I use BIKTAVY?
- 5. What should I know while using BIKTARVY?
- 6. Are there any side effects?
- 7. Product details

1. Why am I using BIKTARVY?

BIKTARVY contains the active ingredients bictegravir, emtricitabine and tenofovir alafenamide in a single tablet.

Bictegravir belongs to a group of antiretroviral medicines known as integrase strand transfer inhibitors (INSTI). Emtricitabine and tenofovir alafenamide belong to a group of antiviral medicines known as nucleoside and nucleotide reverse transcriptase inhibitors (NRTI) and (NtRTI), respectively.

These are combined in one tablet to help control Human Immunodeficiency Virus 1 (HIV-1) infection in adults and children weighing at least 25 kg.

BIKTARVY is used to treat HIV-1 infection in adults and children weighing at least 25 kg.

BIKTARVY lowers the amount of HIV in the blood (viral load). BIKTARVY may also help to increase the number of T cells (CD4+ cells), allowing your immune system to improve. Lowering the amount of HIV in the blood lowers the chance of death or infections that happen when your immune system is weak (opportunistic infections).

HIV infection destroys CD4+ T cells, which are important to the immune system. The immune system helps fight infection. After a large number of T cells are destroyed, acquired immune deficiency syndrome (AIDS) may develop.

BIKTARVY is for people who do not have a HIV virus resistant to BIKTARVY.